<DOC>
	<DOCNO>NCT00742092</DOCNO>
	<brief_summary>Single Center , Double-Blind , Randomized , Placebo-Controlled , Two-Period/Two-Treatment Crossover Study Investigating Effect Miglustat Nasal Potential Difference Patients With Cystic Fibrosis Homozygous F508del Mutation</brief_summary>
	<brief_title>Miglustat Cystic Fibrosis</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Miglustat</mesh_term>
	<mesh_term>1-Deoxynojirimycin</mesh_term>
	<criteria>Aged 12 year old Male female Nonpregnant woman remain nonpregnant 3 month end study . Women childbearing potential must use reliable method contraception . Reliable method contraception female patient include follow : barrier type device ( e.g. , female condom , diaphragm contraceptive sponge ) use ONLY combination spermicide intrauterine device oral contraceptive agent DepoProvera™ ( medroxyprogesterone acetate ) levonorgestrel implant Abstention , rhythm method contraception partner alone NOT reliable method contraception . A woman consider childbearing potential unless meet least one follow criterion : 6 week postsurgical bilateral salpingooophorectomy hysterectomy Premature ovarian failure confirm specialist gynecologist Age &gt; 50 year treat kind HRT least 2 year prior screen , amenorrhea least 24 consecutive month prior screen serum FSH level &gt; 40 IU/L screening . Age &gt; 55 year treat HRT prior screen appropriate medical documentation spontaneous amenorrhea least 24 month . For female patient pediatric age range , reliable method contraception must consider , appropriate . Male patient accept duration study 3 month thereafter use condom procreate child ( case azoospermia ) Cystic fibrosis patient homozygous F508del mutation confirm genetic test Signed informed consent prior studymandated procedure Any condition prohibit correct measurement NPD upper respiratory tract infection Acute upper respiratory tract pulmonary exacerbation require antibiotic intervention within 2 week screen Severe renal impairment ( creatinine clearance &lt; 30 mL/min per Cockroft Gault ) Female patient childbearing potential undergo pregnancy test prior enrollment study History significant lactose intolerance History neuropathy Presence clinically significant diarrhea ( &gt; 3 liquid stool per day &gt; 7 day ) without definable cause within 1 month prior screen Any known factor disease might interfere treatment compliance , study conduct interpretation result drug alcohol dependence psychiatric disease FEV1 &lt; 25 % predict normal Oxygen saturation rest &lt; 88 % Active passive smoking measure use Smokelyzer® Hypersensitivity miglustat excipients Planned treatment treatment another investigationaldrug therapy ( e.g. , gene therapy ) within 1 month prior randomization Breastfeeding , pregnant woman woman plan become pregnant course study .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
</DOC>